Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632917 · ClinicalTrials.gov registry record · Phase 1
Open-Label Pharmacokinetic Study of Final Formulations of ATX-101
A Phase 1 study, sponsored by Kythera Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01632917 is a Phase 1 study that has completed, run by Kythera Biopharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT01632917, a Phase 1 study, has completed, sponsored by Kythera Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The objectives of this trial are to evaluate the safety and tolerability of ATX-101 injections and to characterize the pharmacokinetic profile of the two ATX-101 formulations.
Interventions
- DRUG ATX-101 - U.S.
- DRUG ATX-101 - EU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2012-06 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01632917
The ClinicalTrials.gov registry entry for NCT01632917 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kythera Biopharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ATX-101 - U.S. is the first listed.
NCT01632917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01632917 about?
NCT01632917 is a clinical study titled "Open-Label Pharmacokinetic Study of Final Formulations of ATX-101". The objectives of this trial are to evaluate the safety and tolerability of ATX-101 injections and to characterize the pharmacokinetic profile of the two ATX-101 formulations.
What is the current status of trial NCT01632917?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2012-06. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01632917?
The interventions under investigation include: ATX-101 - U.S. (DRUG), ATX-101 - EU (DRUG).
Who is sponsoring clinical trial NCT01632917?
This trial is sponsored by Kythera Biopharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.